SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)--Jun 8, 2025--
SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; 'Modalis'), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM ® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250608851515/en/
SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM ® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4.
'SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD,' stated Eva Chin, Executive Director of SOLVE FSHD. 'SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials.'
'We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103,' said Haru Morita, CEO of Modalis. 'This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM ® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM ® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD.'
About SOLVE FSHD
SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit https://www.solvefshd.com.
About Modalis Therapeutics Corporation
Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM ® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit https://www.modalistx.com/en/.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250608851515/en/
CONTACT: SOLVE FSHD
Alexandra Grant, House of Wilson
[email protected]
Modalis Therapeutics Corporation
Corporate Planning Department
[email protected]
KEYWORD: MASSACHUSETTS NORTH AMERICA UNITED STATES ASIA PACIFIC JAPAN CANADA
INDUSTRY KEYWORD: RESEARCH GENETICS HEALTH TECHNOLOGY PHILANTHROPY BIOTECHNOLOGY GENERAL HEALTH PHARMACEUTICAL HEALTH OTHER PHILANTHROPY SCIENCE
SOURCE: SOLVE FSHD
Copyright Business Wire 2025.
PUB: 06/08/2025 07:30 PM/DISC: 06/08/2025 07:31 PM
http://www.businesswire.com/news/home/20250608851515/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
41 minutes ago
- Associated Press
Orinas Global Launches New Comprehensive Social Media Marketing Services
Orinas Global, a digital marketing and creative agency based in Tokyo, proudly announces the launch of its new version of Social Media Marketing (SMM) services. 'Our new Social Media Marketing services are built for scalability and flexibility. We're not just running campaigns, we're building lasting cross-cultural connections.'— Orinas Global TOKYO, JAPAN, June 9, 2025 / / -- Orinas Global, a digital marketing and creative agency based in Tokyo, proudly announces the launch of its new version of Social Media Marketing (SMM) services, designed to support brands aiming to expand in both the Japanese and global markets. The new offering provides end-to-end campaign support from strategic planning and content creation to ad boosting and performance analysis , all tailored to fast-changing consumer behavior trends. ■ Key services include: 1. Social Media Marketing: We provide complete social media management services — including strategy planning, content production, ad boosting, and campaign analysis. We can manage all your social media channels simultaneously, such as Facebook, Instagram, Twitter, YouTube, TikTok, LINE Official, and more. 2. Influencer Marketing: Our influencer network includes over 20,000 creators worldwide, with a strong focus on Japan-based talents. We handle everything from campaign planning and influencer outreach to post-campaign analytics. 3. BGM Monetization via YouTube Shorts: Creators can monetize their content using copyright-cleared music provided by our partners, earning revenue through YouTube Shorts views. 4. P2C (Producer-to-Consumer): We support creators in launching their own brands by partnering with Japanese manufacturers. Available product categories include apparel, cosmetics, and more. We manage everything from partner selection and design meetings to material sourcing and product distribution. What sets Orinas apart is its multilingual execution. Whether your content needs to be in English, Japanese, Thai, or more, the team delivers culturally localized campaigns across platforms. ------------------------------------------------------------------------------------- Orinas provides everything: social media strategy, influencer campaigns, offline activations, venue sourcing, and even product opening events in Japan. Flexible pricing and scalable packages make it easy for startups and global brands alike to grow their reach and build localized engagement across borders. ------------------------------------------------------------------------------------- ■ About Orinas Global Orinas Global is a Tokyo-based digital marketing agency specializing in cross-cultural branding, social media strategy, and influencer marketing. With bilingual expertise and local insight, Orinas helps brands succeed globally with campaigns that connect locally. Thinking of launching your product in a new market, but unsure where to begin? Visit us on website Orinas Global Team Orinas Inc. email us here Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Bloomberg
an hour ago
- Bloomberg
BentallGreenOak to Invest $11 Billion in Japanese Real Estate
BentallGreenOak will accelerate real estate investments and hiring in Japan, joining a growing number of global firms that are betting money can be made as local companies offload property assets. The Canadian firm plans to invest more than ¥1.6 trillion ($11 billion) in Japanese property through 2027, mainly in office buildings and hotels, according to BGO's Asia Chairman Fred Schmidt.
Associated Press
2 hours ago
- Associated Press
First Hydrogen Announces Strategic Collaboration with Renewable Thermal Laboratory at the University of Alberta to Advance Nuclear SMR Technology
Vancouver, British Columbia--(Newsfile Corp. - June 9, 2025) - First Hydrogen Corp. (TSXV: FHYD) (OTC Pink: FHYDF) (FSE: FIT) ('FIRST HYDROGEN' or the 'Company') is pleased to announce a strategic collaboration with Professor Muhammad Taha Manzoor from the University of Alberta aimed at advancing Small Modular Nuclear Reactor (SMR) technology, specifically focusing on fuel reactor materials and reactor design optimization taking into consideration the growth of artificial intelligence (AI) data centres as they consume up 10 times more power than normal data centres ( Ithy - Comparative Power Consumption of AI Servers and Normal Servers in Data Centers ). The project will take into consideration the surge in AI data centres and energy needs worldwide. The project will be led by Dr. Manzoor, an expert in molten salt thermal-hydraulics and lead at the Renewable Thermal Laboratory that has projects ranging from thermal energy storage to small modular nuclear reactors. Molten salt, as a coolant and nuclear fuel, is the future of nuclear energy due its: [This table cannot be displayed. Please visit the source.] This collaboration aligns with First Hydrogen's mission to pioneer sustainable, efficient, and safe energy solutions, leveraging nuclear technology to produce green hydrogen and support global decarbonization objectives. First Hydrogen seeks to integrate advanced nuclear technology with green hydrogen production. SMRs, known for their compact design, scalability, and ability to provide a continuous, weather-independent power supply, are the cornerstone of this initiative. By leveraging SMRs, First Hydrogen ensures a stable, cost-effective, and efficient process for producing green hydrogen, addressing the growing demand for clean energy solutions worldwide. The International Energy Agency reported artificial intelligence from data centres will drive electricity demand. By 2030, electricity demand from data centres worldwide is expected to more than double to 945 terawatt hours, more than the entire electricity consumption of Japan today. ( ) According to McKinsey and Company, the AI book is driving significant investment in data centres. Their research indications that approximately $5.2 trillion, in capital expenditures, will be required worldwide by 2030 to meet the increasing demand for computing power. ( ) Dr. Manzoor commented, 'We are excited to collaborate with First Hydrogen on molten salt small modular nuclear reactor research. The signing of this letter of support marks an important first step in what promises to be a series of significant milestones in advancing SMR technology in Canada. This industry-led project will provide students with valuable hands-on experience and help train the next generation of engineers and scientists who will contribute to the growth and diversification of Canada's energy sector.' Balraj Mann, CEO of First Hydrogen, stated, 'We are excited to collaborate with the University of Alberta, leveraging their expertise in nuclear research to significantly advance nuclear fuels for SMRs. This collaboration underscores our commitment to driving innovation in clean energy solutions that will play a critical role in transitioning toward a zero-emission future.' About First Nuclear Corp. ( ) First Hydrogen Corp. is committed to developing and commercializing advanced clean energy solutions, including green hydrogen produced by state-of-the-art Small Modular Reactors. The Company aims to provide scalable, sustainable, and economically viable alternatives to meet global climate goals and enhance energy security. About First Hydrogen Corp. ( ) First Hydrogen Corp. is a Vancouver, Montreal, Germany and London UK-based company focused on zero-emission vehicles, green hydrogen production and distribution. The Company has designed and built two hydrogen- fuel-cell-powered light commercial vehicles ('FCEV'). The FCEV are road-legal in the United Kingdom (excluding Northern Ireland) with 6,000 km of testing completed and have achieved a range of 630+ kilometres on a single refueling. The vehicles have successfully been trialled in real-world conditions with fleet operators in the United Kingdom. On behalf of the Board of Directors of FIRST HYDROGEN CORP. Contact: Balraj Mann First Hydrogen Corp. 604-601-2018 [email protected] Cautionary Note Regarding Forward-Looking Statements This news release contains information or statements that constitute 'forward-looking statements.' Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements, or developments to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by words such as 'expects,' 'plans,' 'anticipates,' 'believes,' 'intends,' 'estimates,' 'projects,' 'potential' and similar expressions, or that events or conditions 'will,' 'would,' 'may,' 'could' or 'should' occur. Forward-looking information may include, without limitation, statements regarding the operations, business, financial condition, expected financial results, performance, prospects, opportunities, priorities, targets, goals, ongoing objectives, milestones, strategies and outlook of First Hydrogen, and includes statements about, among other things, future developments and the future operations, strengths and strategies of First Hydrogen. Forward-looking information is provided for the purpose of presenting information about management's current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. These statements should not be read as guarantees of future performance or results. The forward-looking statements made in this news release are based on management's assumptions and analysis and other factors that may be drawn upon by management to form conclusions and make forecasts or projections, including management's experience and assessments of historical trends, current conditions and expected future developments. Although management believes that these assumptions, analyses and assessments are reasonable at the time the statements contained in this news release are made, actual results may differ materially from those projected in any forward-looking statements. Examples of risks and factors that could cause actual results to materially differ from forward-looking statements may include: the timing and unpredictability of regulatory actions; regulatory, legislative, legal or other developments with respect to its operations or business; limited marketing and sales capabilities; early stage of the industry and product development; limited products; reliance on third parties; unfavourable publicity or consumer perception; general economic conditions and financial markets; the impact of increasing competition; the loss of key management personnel; capital requirements and liquidity; access to capital; the timing and amount of capital expenditures; the impact of COVID-19; shifts in the demand for First Hydrogen's products and the size of the market; patent law reform; patent litigation and intellectual property; conflicts of interest; and general market and economic conditions. The forward-looking information contained in this news release represents the expectations of First Hydrogen as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. First Hydrogen undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should view the source version of this press release, please visit
